蘑菇AV

Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown鈥攁nd possible price war鈥攂etween Novo and Lilly.

Lawmakers investigate telehealth tie-ups with pharma: Despite more scrutiny over potential conflicts of interest, we expect even more Big Pharma D2C launches this year.

Warby Parker joins forces with Target: The D2C eyewear brand will open five shop-in-shops as it doubles down on physical retail.

Senators reintroduce Drug-price Transparency for Consumers Act: If passed, the Act could empower patients to make informed decisions about their healthcare amid a torrent of direct-to-consumer drug ads.

Sanofi鈥檚 Opella secures FDA nod to pursue OTC Cialis study: If Cialis鈥� shift from a prescription drug to over-the-counter product comes to fruition, both consumers and D2C retailers could benefit.

Could Trump鈥檚 second term include a ban on D2C pharma ads? We examine the likelihood of a ban and explore what more oversight of drug ads on TV means for pharma marketers.

Healthcare and pharma companies will lean further into D2C in 2025: They鈥檙e cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry鈥檚 push into D2C won鈥檛 be met without challenges.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what鈥檚 at stake for drugmakers and D2C companies selling compounded weight loss medications.

RFK Jr.鈥檚 pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK鈥檚 plans to cut D2C advertising.

Nike's recent struggles highlight the risks of an ill-timed shift to direct-to-consumer (D2C) sales. The sportswear giant's sales slumped 10% YoY for the quarter ending August 31 as competitors gained market share.

On Holdings鈥檚 sales jumped 34% in Q3: The upstart鈥檚 efforts to boost brand awareness gave lucrative direct-to-consumer sales a lift.

Hims to offer a generic GLP-1 in 2025: It鈥檚 preparing for headwinds if the FDA halts compounded versions of weight loss drugs. But we think its diverse D2C offerings and strong subscriber growth should help insulate it financially.

Paramount鈥檚 Q3 results reflect strong streaming growth: To attain 3.5 million new subscribers and $49 million in DTC profit, it鈥檚 leveraged cost cutting and content innovation to balance revenue pressures from traditional TV.

Walgreens expands D2C telehealth to 30 states: We examine how the move aligns with Walgreens鈥� strategy to rightsize its retail pharmacy business.

Senators probe Pfizer, Eli Lilly about their D2C telehealth platforms: But we don鈥檛 expect a slowdown in Big Pharma鈥檚 push into direct-to-consumer sales. Here鈥檚 why.

Insurance agents marked 鈥榮afe鈥� from disruption: The ups and downs of the direct-to-consumer life insurance market have taught the industry a lot about contemporary consumers and in-person experiences.